Anti-viral treatment in Mild Cognitive Impairment
Anti-Viral Treatment in Mild Cognitive Impairment
Sponsor: Alzheimers Association
Enrolling: Male and Female Patients
IRB Number: 8089
U.S. Govt. ID: NCT04710030
Contact: Betty Ostrager: 646-774-7204 / betty.ostrager@nyspi.columbia.edu
Additional Study Information: There is considerable evidence that viruses, particularly a virus called herpes simplex, are commonly present in the brains of people with memory problems and may cause or contribute to worsening memory. The widely available and generic anti-viral medication Valacyclovir is FDA approved to treat herpes simplex as it is highly effective against herpes virus infections. This experimental study will test whether Valacyclovir is also helpful in treating memory problems in patients who have tested positive for the herpes virus. You may be eligible to participate if you: Have been experiencing noticeable changes in your memory, language, thinking, behavior, and multitasking abilities, or have been diagnosed with Mild cognitive impairment. Have someone willing to provide information about your condition and progress participation will include: Neurological and physical evaluation by a physician, and cognitive and functional assessments, and brain imaging.
This study is closed
Investigator
Davangere Devanand, MD
Do You Qualify?
Have you been experiencing changes in your memory, language, thinking, etc. or been diagnosed with Mild Cognitive Impairment? Yes No
Do you have someone willing to provide information about your condition and progress? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Betty Ostrager
betty.ostrager@nyspi.columbia.edu
646-774-7204